Distribution · GCC · Announced 17 Apr 2025

Apex Pharma → CIGALAH Healthcare

Egypt's Apex Pharma signed a strategic partnership with Saudi distributor Saqqala Healthcare to distribute medicines made at its King Abdullah Economic City plant, its first outside Egypt, with technology transfer and local training.

Parties: Apex Pharma (Egypt) → CIGALAH Healthcare (Saudi Arabia)

Deal type
Distribution
Value
Undisclosed
Territory
Saudi Arabia
Therapeutic area
Multi-therapy
Asset
Chronic-disease portfolio made in KAEC (products not named)
Announced
17 Apr 2025

Our analysis

Why this matters

Apex Pharma signed a strategic partnership with Saudi distributor CIGALAH Healthcare to distribute products manufactured at Apex's plant in King Abdullah Economic City (KAEC), reported on 17 April 2025. The focus is chronic conditions: cardiology, diabetes, psychiatric and neurological disorders, and urology. The partnership also covers knowledge and technology transfer and training of Saudi staff. The signing was attended by Sheikh Yasser Al-Nagi and Apex chairman Dr. Magdy Elba. Value and duration were not disclosed.

The KAEC plant is the first by an Egyptian drugmaker outside Egypt. Apex announced a SAR 300 million first-phase investment in December 2023, and Forbes Middle East reports the roughly $80 million factory was inaugurated in 2025.

The full analysis is free to read with a work email on this page.

Source: Souq Al Dawaa Saudi

Latest deals

All GCC deals → · All distribution deals → · Browse all emerging-market pharma deals →